Iovance Biotherapeutics (IOVA) Research & Development (2011 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Research & Development of $62.5 million for Q1 2026, down 17.74% year-over-year from $76.0 million in Q1 2025, and down 12.24% quarter-over-quarter from $71.2 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Research & Development (2011 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Research & Development for 15 consecutive years, with $62.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 17.74% year-over-year to $62.5 million; the TTM figure through Mar 2026 stood at $288.2 million (up 40.2% YoY), while the FY2025 annual figure was $300.3 million, up 8.7% from the prior year.
- Research & Development fell to $62.5 million in Q1 2026 per IOVA's latest filing, from $71.2 million in the prior quarter.
- Across five years, Research & Development topped out at $87.5 million in Q3 2023 and bottomed at $500000.0 in Q4 2024.
- Historically, Research & Development has averaged $70.7 million across 5 years, with a median of $75.2 million in 2025.
- Annual changes were most pronounced in 2024 — Research & Development tumbled 99.35% — and 2025, when it surged 14140.6%.
- Iovance Biotherapeutics' Research & Development stood at $80.6 million in 2022, then fell by 4.95% to $76.6 million in 2023, then sank by 99.35% to $500000.0 in 2024, then soared by 14140.6% to $71.2 million in 2025, then fell by 12.24% to $62.5 million in 2026.
- Business Quant data shows IOVA's Research & Development at $62.5 million in Q1 2026, $71.2 million in Q4 2025, and $75.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 58.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.85 Mn |
| Mar 31, 2026 | 62.49 Mn |
| Dec 31, 2025 | 71.20 Mn |
| Sep 30, 2025 | 75.17 Mn |
| Jun 30, 2025 | 79.36 Mn |
| Mar 31, 2025 | 75.97 Mn |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 67.04 Mn |
| Jun 30, 2024 | 62.08 Mn |
| Mar 31, 2024 | 79.78 Mn |
| Dec 31, 2023 | 76.59 Mn |
| Sep 30, 2023 | 87.53 Mn |
| Jun 30, 2023 | 86.35 Mn |
| Mar 31, 2023 | 82.73 Mn |
| Dec 31, 2022 | 80.57 Mn |
| Sep 30, 2022 | 72.50 Mn |
| Jun 30, 2022 | 73.41 Mn |
| Mar 31, 2022 | 68.30 Mn |
| Dec 31, 2021 | 75.62 Mn |
| Sep 30, 2021 | 65.36 Mn |